Lutein Supplementation for Diabetic Macular Edema

Italia A. Rivera1,2, Gustavo A. Altamirano1,3, Eleazar L. Padilla3, Adrian H. Heald4 and Gabriela Y.C. Moreno1,3,*

1Hospital Regional de Alta Especialidad de Ixtapaluca; State of Mexico, ZIP 56530, Mexico.
2Interdisciplinary Centre of Health Sciences, Milpa Alta Unit; Instituto Politécnico Nacional, Mexico City, ZIP 12000, Mexico.
3School of Medicine; Instituto Politécnico Nacional, Mexico City, ZIP 06729, Mexico.
4Salford Royal Hospital, University of Manchester and St. Peter’s College, Oxford; Manchester City, ZIP M13 9PL, United Kingdom.

Correspondence: Gabriela Yanet Cortés Moreno, Hospital Regional de Alta Especialidad de Ixtapaluca, Mexico-Puebla Federal Highway Km 34.5, Zoquiapan, Ixtapaluca, Estado de México, México, ORCID: 0000-0002-4506-8223, E-mail: medic_gaby@live.com.mx.

Received: 20 March 2019; Accepted: 15 April 2019


ABSTRACT

Lutein is a natural component of the retina that is acquired in the diet; One of its multiple functions is to capture reactive oxygen species and promote their elimination. People with Diabetes Mellitus have a significant increase in oxidative stress due to protein glycation and activation of the polyol pathway; as a result, they develop diabetic retinopathy that can progress to macular edema and cause severe visual disturbances including central blindness. The lack of lutein in people with macular edema is evident, therefore, they require additional consumption to prevent and reduce the complications. We decided to undertake a review in order to learn more about this supplement, its properties and its beneficial effect on the eyesight of individuals with Diabetic Macular Edema.

Keywords
Carotenoids, Diabetes complications, Zeaxanthin.

Introduction

Diabetic Macular Edema (DME) represents the most frequent cause of blindness in individuals aged 20 to 74 years [1]. This can start to develop at least 7 years before the diagnosis of Type 2 Diabetes Mellitus [1,2]. Studies in Mexico report a prevalence of Diabetic Retinopathy of 33.3% (29.9% with Non-Sight Threatening Retinopathy and 3.4% with Sight Threatening Retinopathy) of which, more than half suffer from DME [3,4]. Currently, existing therapies are limited to invasive pharmacological treatments, however, recent studies have shown efficacy in the treatment of DME after the administration of natural supplements derived from carotenoids. This article provides an overview about Lutein and evidence of its use as an alternative for the treatment of Diabetic Retinopathy and DME.

Carotenoids and their Properties

Carotenoids are natural compounds found in different plant structures and in a great variety of animals, algae, fungi and bacteria. These pigments are responsible for the coloration of flowers and fruits (in order to favor pollination and the scattering of seeds), or animal structures such as feathers and the beaks of certain birds, the exoskeletons of crustaceans and the muscles or skin of certain types of fish [5].

These compounds are considered to be essential to life, owing fundamentally to the functions they carry out in relation to photosynthesis (harvesting light pigments, photoprotection) [5,6].

There are two types of carotenoids: carotenes, which contain no oxygen in their terminal rings (example: β-carotene, lycopene) and xanthophylls, which contain oxygen in their terminal rings (example: lutein and zeaxanthin). These four are the most abundant in human blood [7,8]. However, the one found in the greatest proportion in plasma is lutein, which also makes up 90% of the pigment in the macula (central zone of the retina and area of greatest ocular vision) [9] (Figure 1).

Carotenoids are isoprenoids (unsaponifiable simple lipids) that have properties of light-absorption through the presence of 7 or more conjugated double bonds and its principal benefit is the absorption of ultraviolet light (high-energy light, originating from...
Lutein and biological functions

Lutein is the most common carotenoid found in nature, as well as that principal xanthophyll of the pigment complex. It is a dihydroxilated derivative of α-carotene, which, having substituted beta-rings, has no provitamin A activity. In addition, human beings cannot synthesize this nutrient, so it must be acquired through the consumption of foods such as egg yolk, broccoli, orange or chard spinach [11].

Lutein is a yellowish-orange pigment with a dual mechanism, inactivating singlet oxygen (energetically excited forms of molecular oxygen) and trapping free radicals. It also possesses anti-inflammatory and neuroprotective properties [12]. Its neuroprotective function lies in the preservation of levels of synaptophysin, a synaptic vesicle protein that is important for the release of neurotransmitters and activity of the synaptic network. This protein is abundant in the inner plexiform layer of the retina. In addition, lutein suppresses the activation of the extracellular signal-regulated kinases (ERKs), a kinase that degrades Synaptophysin [12].

Anti-inflammatory function is achieved through the induction of changes in the expression of genes related to inflammation, demonstrated in the retinal pigment epithelium (RPE). Antioxidants inhibit the retinal increase in the redox-sensitive nuclear transcription factor-B (NF-κB, a transcriptional factor that controls the expression of many genes involved with inflammation) and what prevents the development of diabetic retinopathy [12].

Its function as an antioxidant in human tissue decreases the risk of cardiovascular disease and certain kinds of cancer; however, it presents the greatest benefit in ocular problems, especially those concerning retinal affections, it being a tissue with a high exposure to oxidative stress [13]. The retina is the neurosensory tissue of the eye and is extremely rich in membranes with polyunsaturated lipids, a feature that makes it especially sensitive to the deleterious action of free radicals derived from oxygen and nitrogen [14]. An event that lead to the discovery of the effects of this antioxidant on the human body took place in 1904, when a Japanese bacteriologist, Inawashiro Noguchi Seisaku, uncovered the causal agent of treponema (Chlamydia trachomatis), which causes a contagious granular conjunctivitis that can lead to blindness. Alongside this investigation, he studied syphilis; whereby he discovered the spirochaete Treponema pallidum, which was found in the brain and in the spinal cord of those affected and came up with a method of diagnosis that consisted of a modification of the Wassermann reaction with lutein, a method which was dubbed the Noguchi reaction with lutein in his honor [15].

From that point on, studies were made on the functions of lutein, with allowed for its commercialization in powder form and its use as an additive in certain foods, as well as its use as a supplement in capsules for eyesight.

Lutein for Diabetic Macular Edema.

Currently, lutein is used to prevent Age-Related Macular Degeneration (ARMD), however, there is evidence supporting its efficacy in reducing diabetic macular edema. Bo-Jie Hu, et al. (16) proved its effects by carrying out an intervention on 30 patients suffering from non-proliferative diabetic retinopathy, to which they administered 6 mg of lutein and 0.5 mg of zeaxanthin orally over a span of three months, and made a comparison with a second group that did not receive lutein, but did have non-proliferative diabetic retinopathy, and a control group of healthy people; the results showed that foveal thickness diminished in 83% of patients after medication [16].

L. Brazionis et al., reported that people with diabetes have lower plasma concentrations of α-Carotene β-Carotene, Lutein, zeaxanthin, Lycopene, compared to control group [17]. M. Moschos et al, confirms that the Macular Pigment Optical Density (MPOD) and Contrast Sensitivity (CS) increase after the carotenoid supplementation [18].

Likewise, F. Granado et al. tried supplementation with capsules of α-tocopherol, cis-lutein and trans-lutein in order to find out if plasma lutein concentrations are related to oxidative stress, in his study he reports a non-significant decrease of plasma lutein levels in Type 1 diabetics, probably influenced by the lipid’s metabolism of each person [19] (Table 1).

Future directions and challenges

This supplement would represent an excellent therapeutic option for individuals suffering from diabetic macular edema, since treatment for this pathology is currently limited to intravitreal injections of antiangiogenic pharmaceuticals or corticosteroids and laser; however, these therapies are only effective in less than a third of those who undergo them and all this at a high cost [20,21].

Basing ourselves on these investigations, we have decided to carry out clinical studies in Mexico to compare the effects of this natural antioxidant to existing therapies for treating Diabetic Macular Edema. It is necessary that these clinical trials become the foundation on which to carry out new studies that prove the
Table 1: Summary of studies investigating the relationships among, Diabetes, Diabetic Retinopathy, supplementation of Lutein/analogs & derivatives.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>N</th>
<th>Population of study</th>
<th>Duration</th>
<th>Treatment</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Moschos et al. [18]</td>
<td>2017</td>
<td>60</td>
<td>Type 2 Diabetes without diabetic retinopathy</td>
<td>2 years</td>
<td>One capsule a day with: - lutein (10 mg) - zeaxanthin (2 mg) - meso-zeaxanthin (10 mg)</td>
<td>( \text{BCV A} ) = \text{Best corrected Visual Acuity} \</td>
</tr>
<tr>
<td>Hu BJ et al. [16]</td>
<td>2011</td>
<td>90</td>
<td>Nonproliferative diabetic retinopathy</td>
<td>3 months</td>
<td>One capsule a day with: - Lutein 6mg/d - Zeaxanthin 0.5mg/d</td>
<td>( \text{DR Group} = \uparrow \text{L/Z} (0.5490 \mu g/mL \text{and} 0.2816 \mu g/mL) ) \</td>
</tr>
<tr>
<td>L. Brazionis et al. [17]</td>
<td>2009</td>
<td>111</td>
<td>Type 2 Diabetes</td>
<td></td>
<td>Not taking carotenoid supplements, only measurements</td>
<td>( \downarrow \text{L/Z (mmol/L)} 0.36 \text{vs DR} 0.34 (p=0.736) ) \</td>
</tr>
<tr>
<td>F. Granado et al. [19]</td>
<td>2002</td>
<td>18</td>
<td>Type 1 Diabetes</td>
<td>21 days</td>
<td>One capsule a day with: -12 mg all-trans-lutein - 3 mg of 13/15-cis-lutein - 3.3 mg of a-tocopherol</td>
<td>( \uparrow \text{Lutein (mmol/L)} 20.76 \pm 13.72 \text{vs DM1 = 21.29} \pm 14.43 \text{(p= NS)} ) \</td>
</tr>
</tbody>
</table>

usefulness of Lutein so it can be opportunistically used in cases of Diabetic Retinopathy and Diabetic Macular Edema.

Acknowledgments

We thank Dr. Tania Villagra Sanjurjo for share her clinical experience in Diabetic Retinopathy.

References

7. https://es.calameo.com/read/0017523139dd3a95aa24c